Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp is positioned favorably due to increasing physician comfort with chronic use of its lead candidate, apitegromab, which enhances expectations for meaningful improvements in patient independence and reduced caregiver burden. Positive feedback from Key Opinion Leaders (KOLs) indicates that the treatment may lead to sustained functional gains in patients with Spinal Muscular Atrophy, reinforcing confidence in the drug's efficacy and its market potential. The company's valuation methodology has been refined, reflecting optimism regarding future revenue growth, leading to an upward adjustment in price targets based on lower share counts and improved operational readiness for the product launch.

Bears say

Scholar Rock Holding reported a net loss of $91.0 million in its Q4 2025 results, which is better than consensus expectations but still reflects ongoing financial challenges. The delay in the anticipated launch of apitegromab has led to a downward revision in peak sales projections, now estimated at $1.7 billion by 2035, highlighting uncertainty in revenue potential. Additional risks include potential regulatory approval delays and competitive dynamics that could hinder market share, further contributing to a negative outlook for the company’s stock.

SRRK has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 11 analysts, SRRK has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.